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MicroRNAs (miRNAs) with tumor-suppressor potential might have therapeutic applications in multiple myeloma (MM) through
themodulation ofstillundiscoveredmolecularpathways.Here,weinvestigatedtheeffectsofenforcedexpression ofmiR-29b on
the apoptotic occurrence in MM and highlighted its role in the context of a new transcriptional loop that is ﬁnely tuned by the
proteasome inhibitor bortezomib. In details, in vitro growth inhibition and apoptosis of MM cells was induced by either transient
expression of synthetic miR-29b or its stable lentivirus-enforced expression. We identiﬁed Sp1, a transcription factor endowed
with oncogenic activity, as a negative regulator of miR-29b expression in MM cells. Since Sp1 expression and functions are
regulated via the 26S proteasome, we investigated the effects of bortezomib on miR-29b-Sp1 loop, showing that miR-29b levels
were indeed upregulated by the drug. At the same time, the bortezomib/miR-29b combination produced signiﬁcant pro-apoptotic
effects. We also demonstrated that the PI3K/AKT pathway plays a major role in the regulation of miR-29b-Sp1 loop and induction
of apoptosis in MM cells. Finally, MM xenografts constitutively expressing miR-29b showed signiﬁcant reduction of their
tumorigenic potential. Our ﬁndings indicate that miR-29b is involved in a regulatory loop amenable of pharmacologic
intervention and modulates the anti-MM activity of bortezomib in MM cells.
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MicroRNAs (miRNAs) are a class of naturally occurring small
non-coding RNA molecules of 19–25 nucleotides that
negatively regulate gene expression at post-transcriptional
level by base pairing with the 30 untranslated region (UTR) of
their target mRNAs. It is believed that if this base pairing is
perfect, the mRNA is cleaved and degraded.
1 However,
translational repression by imperfect pairing is the prevalent
activity of human miRNAs.
2
Since a single miRNA is able to bind to and consequently
regulate approximately up to 100 different transcripts,
3,4
miRNAs truly represent master regulators of gene expression
and inﬂuence virtually all cell activities and events, including
cell proliferation, cell death, differentiation, metabolism,
infection and cancer.
5 Deregulation of miRNA expression
commonly occurs in human cancer and is involved in cancer
initiation and progression;
6,7 miRNA expression proﬁles have
prognostic implications,
8 while targeting the miRNA network
exerts anti-tumor effects in vivo,
9 indicating a great therapeu-
tic potential of miRNAs for cancer treatment.
10 Noteworthy,
miRNAs that are deleted or downregulated in malignancies
generally play a tumor-suppressor function, whereas those
that are upregulated act as transforming oncogenes.
11,12
However, the correlation between expression levels and
oncogenetic/suppressor function remains still unclear.
13
Multiple myeloma (MM) is an hematologic malignancy
characterized by the accumulation of tumor plasma cells
(PCs) in the bone marrow (BM), which causes bone
destruction and marrow failure.
14 Although deﬁned histologi-
cally as a single entity, MM encompasses a plethora
of disease subsets characterized by distinct genomic
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www.nature.com/cddisabnormalities, which possibly mark different pathogenetic
pathways and in most cases retain prognostic value. Such
molecular events, beside reprogramming the cell proliferation
capacities, ﬁnely tune the interaction between malignant PCs
and BM stromal cells (BMSCs) within the human BM
microenvironment (huBMM).
15,16 The huBMM plays a critical
role in promoting MM cell growth, survivaland development of
drug resistance; moreover, this cell-to-cell interaction pro-
vides a framework for the design of novel therapeutic
strategies.
17 In the last years, the huge advancement in the
knowledge of MM pathogenesis allowed some drugs, such as
thalidomide,
18 bortezomib
19 and lenalidomide,
20 to reach the
clinical side, with signiﬁcant improvement in terms of disease
control and long-term survival.
21 However, while many other
novel agents are presently in advanced phase of preclinical
investigation,
22–25 MM is still an incurable disease and novel
therapeutic strategies are urgently needed.
To date, few studies have investigated the expression of
miRNAs in MM, mostly by comparing the miRNA expression
proﬁle of BM-derived PCs of healthy donors with that of the
PCs from subjects with monoclonal gammopaty of undeter-
mined signiﬁcance (MGUS) or MM patients; from these
studies, it clearly emerges that several miRNAs are deregu-
latedinprimaryorestablishedMMcelllinesandareinvolvedin
keyroles in regulatory networks controllingproliferation and/or
survival.
26–28 Among miRNAs frequently deregulated in
human cancer, miR-29b is of great interest due to its potential
for therapeutic applications. miR-29b belongs to a family
whose members are located at two loci on different chromo-
somes: miR-29b1/29a at 7q32, and miR-29b2/c at 1q23.
29 An
aggressive clinical behavior of B-cell chronic leukemia
correlates with reduced levels of miR-29b and miR-181 and
increasedexpressionof their common target, theB- andT-cell
malignancy speciﬁc oncogene, TCL1.
30 Several additional
miR-29b targets, including the anti-apoptotic protein
Mcl-1,
31,32 the phosphatidyl inositol-3 kinase,
33 the DNA
methyltransferase 3A and B,
34 the extracellular matrix
proteins, collagens
35 and cell-cycle regulators,
36 may con-
tribute to the malignant phenotype and metastatic progres-
sion.
29Therefore,itisconceivablethattheenforcedexpression
of miR-29b in cancer cells may interfere with multiple
oncogenic mechanisms, including tumor-suppressor promoter
methylation,
34 extracellular matrix remodeling
35 and anti-
apoptotic signaling.
31 Moreover, it is of note that miR-29b/
miR-29aaredownregulatedbytheactivationofmultiplegrowth
andsurvivalpromotingsignalingsuchasc-myc,Hedgehogand
NF-kBp a t h w a y s ,
37 while miR-29b overexpression induces
apoptosis in vitro
31,32 and exerts anti-tumor effects in vivo in
acute myeloid leukemia and rabdomyosarcoma.
36,38
Based on these premises, we investigated the in vitro and
in vivo effects of synthetic miR-29b on MM cell proliferation
and apoptosis and explored on the molecular pathways that
underline or counteract miR-29b function. Finally, we inves-
tigated the role of bortezomib in upregulating miR-29b levels
thus antagonizing the escape mechanisms from miR-29b
induced growth inhibition and apoptosis in MM cells.
Results
Expression of miR-29b in primary CD138
þ cells and
established MM cell lines. We evaluated by high-density
microarrays miRNA proﬁling the expression of miR-29b in
primary CD138
þ cells from intramedullary MM (n¼38) or
PC leukemia (PCL; n¼2) patients. As shown in Figure 1a,
we found wide variation of miR-29b expression with 55% (21/
38) of MM and 100% (2/2) of PCL patients bearing low miR-
29b (o100 relative expression levels – REL – in arbitrary
units referred to the median value).
In addition, we evaluated miR-29b expression by quantita-
tive RT–PCR (qRT–PCR) in a panel of 10MM cell lines,
including OPM1, INA-6, OPM2, NCI-H929, MM1S, LR5,
DOX6, SKMM1, KMS12-PE, and RPMI-8226. Heteroge-
neous levels of miR-29b were detected, suggesting again a
deregulated activity (Figure 1b).
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Figure 1 miR-29bexpressionin MM primary samples and cell lines. (a) miR-29b expression levels obtained by Agilent-miRNA proﬁling of 723 humanand 76 human/viral
miRNAs. Histogram bars represent miR-29b expression values in 38 MM and 2 PCL patients, normalized by aroma.light-package for Bioconductor. (b) Quantitative RT–PCR
analysis of miR-29b using total RNA from 10 MM cell lines. Raw Ct values were normalized to RNU44 housekeeping snoRNA and expressed as DDCt values referenced to
miR-29b levels in PBMC. Values represent mean of three different experiments±S.E. (c) Quantitative RT–PCR of miR-29b in NCI-H929 cells co-cultured with MM patient-
derived BMSCs and then immunopuriﬁed by immunomagnetic sorting with anti-CD138 beads. Raw Ct values were normalized to RNU44 housekeeping snoRNA and
expressed as DDCt values calculated using the comparative cross threshold method. miR-29b levels in NCI-H929 harvested after 6h of co-culture were set as internal
reference. Data are the average of two independent experiments performed in triplicate. P-values were obtained using two-tailed t test. *Po0.01
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Cell Death and DiseaseMoreover, to study the inﬂuence of the huBMM on miR-29b
expression, serum-starved NCI-H929 cells were cultured
adherent to patient-derived BMSCs, and the expression of
miR-29b was analyzed by qRT–PCR at 6, 12, and 24h in MM
cells. Importantly, adhesion of NCI-H929 cells to BMSCs
induced a decrease of miR-29b expression after 12h
(Figure 1c), suggesting that low miR-29b might indeed be
associated with the supportive effect exerted by huBMM on
MM cell growth and survival. Similar results were obtained
with RPMI-8226 cells (Supplementary Figure 1).
Synthetic miR-29b reduces cell growth and induces
apoptosis in MM cell lines in vitro. On the basis of the
previous data, we studied the in vitro activity of miR-29b
against different MM cell lines including IL-6-dependent (INA-
6) and IL-6-independent (RPMI-8226, OPM1, NCI-H929,
SKMM1) MM cells. Cells were electroporated with synthetic
miR-29b or scrambled (NC) oligonucleotides and viable cell
numbers were determined by trypan blue exclusion assay at
different time points (Figure 2; transfection procedures are
reported in Supplementary materials and methods). To
conﬁrm the successful transfection, qRT–PCR analysis
of miR-29b was performed on MM cells 24h later
(Supplementary Figure 2). As shown in Figures 2a–e,
overexpression of miR-29b resulted in a signiﬁcant inhibition
of cell growth of MM cell lines starting 48h after electropora-
tion. Moreover, this effect was independent of IL-6 since it
occurred in all cell lines. Interestingly, growth inhibition was
associated to upregulation of the cell-cycle inhibitors p21 and
p27, both observed 24h after cell transfection with synthetic
miR-29b (Figure 2f; for western blotting procedures, see
Supplementary materials and methods).
We also found that transfection of synthetic miR-29b in
SKMM1 and NCI-H929 MM cells signiﬁcantly inhibited colony
formationinmethylcellulosecultures(55and35%reductionin
colonies, respectively; Figures 2g and h).
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Figure 2 miR-29b-enforced expression triggers anti-proliferative and pro-apoptotic effects in MM cells. Cell growth curves of (a) RPMI-8226, (b) SKMM1, (c) OPM1,
(d)INA-6,and(e)NCI-H929transfectedwithsyntheticmiR-29b(miR-29b)orscrambledoligonucleotides(NC).Averagedvaluesofthreeindependentexperimentsareplotted
including±S.D. P-values were obtained using two-tailed t-test *Po0.01;
 Po0.05. (f) Immunoblot of p21
WAF1 and p27
KIP1 in SKMM1 and NCI-H929 cells 24h after
transfection with synthetic miR-29b or scrambled oligonucleotides (NC). Colony formation assay of SKMM1 (g) and NCI-H929 (h) after transfection with synthetic miR-29b or
scrambled oligonucleotides (NC). Six hours after transfection, cells were counted and seeded in triplicate at 200cells/ml in 18-well plates containing methylcellulose-based
medium. After 2 weeks, colony formation was scored by counting colonies including 4100cells. Data indicate the percentage of colonies in the miR-29b methylcellulose
cultureswithrespecttocontrol±S.E.forthreeindependentexperiments.*Po0.01.(i)AnnexinV-stainingofSKMM1andNCI-H929cells48haftertransfectionwithsynthetic
miR-29b or scrambled oligonucleotides (NC). The percentage of Annexin-V-positive cells is reported. Data are the average of three independent experiments±S.D.
*Po0.01;
 Po0.05.(j)Caspase3/7activityassaywasperformedinSKMM1andNCI-H929cells48haftertransfectionwithsyntheticmiR-29borscrambledoligonucleotides
(NC). Transfected cells were grown in 96-well microplates and luminescence was measured using the Caspase 3/7 Glo assay (Promega). Results are expressed as fold
increaseofcaspaseactivitywithrespecttoNC-transfectedcells,ofatleastthreeindependentexperiments.*Po0.01.(k)Immunoblotof cleavedcaspase3andsurvivin,48h
after transfection of SKMM1 and NCI-H929 cells with synthetic miR-29b or scrambled oligonucleotides (NC). Loading control was performed using GAPDH
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Cell Death and DiseaseMoreover, we evaluated the effects of stably enforced
expression of the miR-29b gene carried by lentiviral vectors in
MM cells. SKMM1, U266, and RPMI-8226 cell lines were
transduced by a lentiviral miR-29b expression vector and
subsequently selected by Zeocin (see Supplementary
Materials and methods and Supplementary Figure 3A). We
found that stable expression of miR-29b strongly reduced cell
survival in a time-dependent manner, as demonstrated by
MTS assay (Supplementary Figure 3B–D).
We next examined, by Annexin V/7AAD assay, whether
apoptotic events occurred in cells transfected with miR-29b.
As shown in Figure 2i, ectopic expression of miR-29b
triggered apoptosis at 48h in both SKMM1 and NCI-H929
cells (about twofold increase). Importantly, we found that
apoptotic events induced by miR-29b were associated with
reduced survivin levels and with caspase 3 activation, as
revealed by increased caspase 3/7 activity using an enzy-
matic assay (Figure 2j) and by enhanced caspase 3 cleavage
and reduced survivin expression in western blotting experi-
ments (Figure 2k). Conversely, transfection of miR-29b
mimics did not activate caspase 8 in this cell system (data
not shown).
Taken together, these results indicate that miR-29b is a
negativeregulatorofMMcellgrowthandinducerofapoptosis.
miR-29b regulates CDK6 and MCL-1 in MM cells. miR-
29b is known to exert anti-proliferative and pro-apoptotic
effects in several human cancers by targeting genes involved
in cell-cycle progression and/or apoptosis inhibition.
31,33,36
Based on this consideration, we focused on MCL-1 and
CDK6, which are overexpressed in MM and play a pivotal
role in apoptosis and cell-cycle regulation, respectively.
Enforced expression of miR-29b in SKMM1 cells resulted in
a signiﬁcant downregulation of both MCL-1 and CDK6
mRNAs (Figure 3a) and proteins (Figure 3b), 24h after cell
transfection. As shown in Figure 3b, transfection of miR-29b
also resulted in decreased Rb Ser
780 phosphorylation. Thus,
miR-29b indirectly affected the Rb phosphorylation status,
likely by targeting CDK6 that is known to regulate Rb
phosphorylation.
39 These results were also reproduced in the
NCI-H929 cell line: transfection with miR-29b decreased
CDK6 and MCL-1 at both mRNA (Figure 3c) and protein
levels (Figure 3d). Densitometric analysis of blots is reported
in Supplementary Figure 4. Conversely, inhibition of miR-29b
in SKMM1 cells by means of antagomirs (Figure 3e) resulted
in upregulation of both CDK6 and MCL-1 mRNAs (Figure 3f).
miR-29b exerts anti-MM activity in vivo. Effect of miR-29b
on tumorigenic potential of MM cells was evaluated in vivo.
NCI-H929 cells were transduced with a lentivirus expressing
miR-29b (pMIF-miR-29b) or the empty vector (pMIF). These
cells were inoculated in a cohort of 12 SCID mice, and tumor
formation was monitored. As shown in Figure 4a, enforced
expression of miR-29b reduced the growth of MM xenografts
compared with the control group (Po0.0001), with an
average size of tumors of 617±60S.D. versus
385±60S.D. at day 23. This effect resulted into a signiﬁcant
survival advantage for mice engrafted with miR-29b-tras-
duced MM cells (Figure 4b). Quantitative analysis carried
out in excised tumors demonstrated a more than ﬁvefold
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Cell Death and Diseaseincrease of miR-29b expression in pMIF-miR-29b-trans-
duced tumors compared with controls (Figure 4c) that was
associated to increased in vivo apoptosis and reduced
proliferation, as shown by IHC staining of excised tumors
(Figure 4d). A downregulation of CDK6 and MCL-1 proteins
was also observed in lysates from retrieved xenografts
(Supplementary Figure 5).
All together, these ﬁndings indicate that miR-29b
exerts in vivo anti-MM activity mediated by apoptosis
occurrence, providing a strong rationale for clinical develop-
ment of miR-29b.
Evidence of a miR-29b-Sp1 regulatory loop in MM
cells. Among miR-29b validated targets, we focused our
attention on Sp1, a transcription factor that regulates the
expression of cell-cycle, differentiation, and apoptosis-
related genes. In fact, we have recently shown that high
Sp1 activity is a feature of MM cells and that it can be
therapeutically targeted.
40
We investigated the role of miR-29b on Sp1 mRNA
regulation by transfecting into MM cells a luciferase reporter
vector that contains the 30UTR region of Sp1 predicted to
interact with miR-29b. A marked reduction in the Luciferase/
Renilla ratio was seen in cells transfected with Sp1 construct
together with synthetic miR-29b but not with the control
(scrambled oligonucleotides; Figure 5a). Moreover, transfec-
tion of miR-29b mimics into SKMM1 or NCI-H929 cells
decreased Sp1 expression at both mRNA (Figure 5b) and
proteinlevels(Figure5c).Conversely,inhibitionofmiR-29bby
miR-29b-antagomiR transduction resulted in increased Sp1
mRNA levels (Figure 5d), demonstrating that Sp1 is regulated
by miR-29b in MM cells.
Since miRNAs are frequently involved in feedback loops
where they target factors that negatively regulate their own
expression,
41 we investigated whether Sp1 was able to affect
miR-29b expression in MMcells. To address this question, we
evaluated if Sp1 was able to transcriptionally target miR-29b.
Consistently withSp1-dependenttranscriptional repressionof
miR-29a/b1 promoter, we found that enforced expression of
Sp1 (Supplementary Figure 6) decreased promoter activity in
SKMM1 and NCI-H929 cells by about 70 and 60%,
respectively (Figure 5e); as a consequence, Sp1 overexpres-
sion was associated with reduced miR-29b levels (Figure 5f).
Moreover, we performed loss-of-function experiments in
SKMM1 cells by means of shRNAs against Sp1. As shown
in Figure 5g, silencing of Sp1 increased miR-29b levels.
The role of Sp1 in miR-29b regulation was additionally
elucidated by treating SKMM1 cells with mithramycin-A, a
previously reported Sp1 inhibitor.
42 Again, exposure to
mithramycin-A led to decrease in Sp1 protein expression
(not shown) and increased miR-29b levels (Figure 5h).
miR-29b expression is regulated by bortezomib. Sp1
expression and functions are, at least in part, regulated via
the 26S proteasome, a common pathway controlling the
degradation of a plethora of other survival factors.
43 Some
authors reported that the 26S proteasome inhibitor bortezo-
mib interferes with Sp1/NFkB activity.
44 To evaluate the
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Cell Death and Diseasepotential regulatory role of bortezomib on the miR-29b-Sp1
loop, NCI-H929 cells were treated for 24h with vehicle alone
or bortezomib 2, 5, and 10nM. Bortezomib treatment led to a
dose-dependent increase in apoptotic cells (Figure 6a)
together with downregulation of Sp1 (Figure 6b), and
upregulation of miR-29b (Figure 6c). Notably, miR-29b
upregulation by bortezomib was further demonstrated in
SKMM1 and U266 cells (Figure 6d). A relevant ﬁnding was
that primary CD138
þ cells immunopuriﬁed from peripheral
blood of a PCL patient also demonstrated upregulation of
miR-29b 24h after treatment with bortezomib (1.3mg/m
2)a s
compared with PCs before treatment (Figure 6e).
Previous reports showed that bortezomib promotes Sp1
downregulation in MM cells through caspase 8 activation.
45
To evaluate whether modulation of caspase 8 activity could
also affect miR-29b levels, NCI-H929 cells were treated with
bortezomib alone or in combination with caspase 8 inhibitor
Z-IETD-FMK. We found that caspase 8 inhibition abrogated
bortezomib-induced miR-29b upregulation (Figure 6f).
miR-29b potentiates the anti-MM activity of bortezomib.
To evaluate if Sp-1/miR-29b loop has a role in controlling the
apoptotic process in MM cells, we investigated the contribu-
tion of miR-29b in the response of MM cells to bortezomib.
Indeed, enforced expression of miR-29b strongly increased
bortezomib-induced growth inhibition (Figure 7a) and apop-
tosis (Figures 7b and c) in SKMM1 cells. This effect was not
limited to SKMM1 cells, as miR-29b mimics signiﬁcantly
enhanced bortezomib effects in NCI-H929 (Figure 7d–f). As
a further proof that miR-29b potentiates bortezomib sensi-
tivity in MM cells, we antagonized miR-29b in SKMM1 cells
by stably expressing antagomiR-29b through lentivirus
transduction: as expected, antagomiR-29b-expressing cells
showed a proliferative advantage and were less susceptible
to bortezomib-induced growth inhibition (Figure 7g) and
apoptosis (Figure 7h) as compared with controls. These
ﬁndings strongly suggest an exciting translational potential
and open a novel scenario for miR-29b mimics in the
treatment of MM.
PI3K/AKT regulates miR-29b-Sp1 loop in MM cells.
Finally, we explored whether the PI3K/AKT pathway,
which plays a pivotal role in the regulation of MM cell
proliferation, survival and drug resistance,
46,47 could regulate
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Figure 5 Regulatory feedback between miR-29b and its target Sp1. (a) Dual-luciferase assay of SKMM1 and NCI-H929 cells co-transfected with ﬁreﬂy luciferase
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 Po0.05
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Cell Death and DiseasemiR-29b-Sp1 loop. We found that overexpression of a
dominant active AKT construct in NCI-H929 cells dramati-
cally reduced miR-29b levels and concomitantly led to Sp1
upregulation (Figure 8a; transfection procedures are
reported in Supplementary materials and methods). More-
over, as a further proof of the negative regulation exerted by
PI3K/AKT on miR-29b expression, inhibition of PI3K by
LY294002 increased miR-29b and reduced Sp1 protein
levels. Functionally, overexpression of AKT was able to
suppress miR-29b-dependent increase of caspase 3/7
activity (Figure 8c), whereas treatment with LY294002
potentiated miR-29b-dependent apoptosis (Figure 8d).
Importantly, miR-29b was demonstrated to be a negative
regulator of PI3K/AKT pathway, since transfection of
synthetic miR-29b mimics resulted in reduced AKT phos-
phorylation at S473 together with reduced phosphorylation of
the AKT substrate glycogen synthase kinase-3b (GSK-3b)a t
S9 and upregulation of PTEN protein levels. Moreover, we
provided preliminary evidence that miR-29b mimics transfec-
tion represses signals mediated by mTOR, as assessed by
reduced phosphorylation of 4E-BP1 at S65 (Figure 8e).
Altogether, these results delineate a novel druggable
microcircuitry in MM cells (an explanatory cartoon is included
in Supplementary Figure 7).
Discussion
In this report, we demonstrate that the enforced expression of
miR-29b in MM cell lines inhibits cell growth and triggers
apoptosis in vitro. Importantly, the in vivo ability of miR-29b to
induce apoptosis was also demonstrated in a murine model of
human MM. Our experimental platform was based on MM
xenografts bearing cells with constitutive expression of miR-
29b after lentiviral transduction. Our ﬁndings represent a clear
evidence that miR-29b may efﬁciently prevent the tumor
formation in a preclinical in vivo model of MM.
To assess the mechanisms of apoptosis induction by miR-
29b, we studied the effects of synthetic miR-29b mimics on
the expression of the transcription factor Sp1. In fact, miR-
29b,asothermiRNAs,isabletodownregulategenesinvolved
in proliferation and inhibition of apoptosis, and this property
can explain the growth-inhibitory and pro-apoptotic effects
triggered by miR-29b in MM cells. Moreover, we recently
showed that increased Sp1 activity promotes MM cell growth
and survival and its inhibition has therapeutic value in
preclinical models of MM.
40 Indeed, here we found that miR-
29b negatively regulates Sp1 expression in MM cells. The
30UTR of Sp1 contains four putative miR-29b-binding sites as
predicted by Pictar
48 and two revealed by TargetScan 4.2
softwares.
49 We validated miR-29b regulatory activity by
luciferase reporter assay aswell as bySp1 mRNA and protein
expression analysis, conﬁrming that miR-29b is able to
downregulate Sp1.
Recent studies have also characterized the mechanisms
involved in miR-29b regulation. Speciﬁcally, several cis
elements in the proximal region of miR-29a/b1 promoter have
been identiﬁed that would account, at least in part, for the
transcriptional regulation.
37 Consistently with previous ﬁnd-
ings showing Sp1-binding sites on miR-29b promoter,
44 we
found that Sp1, which is a miR-29b target, negatively
regulates miR-29b: in fact, Sp1 overexpression leads to
miR-29b transcriptional inhibition, whereas Sp1 silencing by
70
60 *
Bortezomib
(nM) 0 2 5 10
Sp1
GAPDH
50
40
A
p
o
p
t
o
t
i
c
 
c
e
l
l
s
 
(
%
)
30
20
10
0
2
4
6
8
10
12
14
0
2
3
1
4
0
2
3
1
4
5
0
2
4
m
i
R
-
2
9
b
 
e
x
p
r
e
s
s
i
o
n
l
e
v
e
l
s
 
(
2
-
Δ
Δ
C
t
)
m
i
R
-
2
9
b
 
e
x
p
r
e
s
s
i
o
n
l
e
v
e
l
s
 
(
2
-
Δ
Δ
C
t
)
m
i
R
-
2
9
b
 
e
x
p
r
e
s
s
i
o
n
l
e
v
e
l
s
 
(
2
-
Δ
Δ
C
t
)
m
i
R
-
2
9
b
 
e
x
p
r
e
s
s
i
o
n
l
e
v
e
l
s
 
(
2
-
Δ
Δ
C
t
) 6
vehicle
bortezomib
*
*
8
0
SKMM1 U266
vehicle
bort
bort + Z-IETD-FMK
vehicle
bort 2nM
bort 5nM
before
treatment
after
treatment
bort 10nM
vehicle
bort 2nM
bort 5nM
*
bort 10nM
Figure6 BortezomibmodulatesmiR-29bexpressionlevelsinMMcells.(a)AnnexinV-stainingofNCI-H929cells24haftertreatmentwithvehicleorbortezomib(indicated
asbort)2,5,or10nM.
 Po0.05.(b)Immunoblotof Sp1inNCI-H929cellstreatedfor24hwithvehicleor bortezomib(indicatedasbort)5,10,or 20nM.GAPDHwasusedas
loading control. Quantitative RT–PCR of miR-29b in (c) NCI-H929 cells treated with vehicle or 2, 5, or 10nM bortezomib for 24h or (d) SKMM1and U266 treated with 10nM
bortezomib or vehicle for 24h. Raw Ct values were normalized to RNU44 housekeeping snoRNA and expressed as DDCt. *Po0.01;
 Po0.05. (e) Quantitative RT–PCR of
miR-29binCD138
þ cellsimmunopuriﬁedfromperipheralbloodofaPCLpatient,24haftersystemictreatmentwith1.3mg/kgbortezomib.Normalizationwasperformedusing
RNU44 snoRNA and DDCt calculations. *Po0.01. (f) Quantitative RT–PCR of miR-29b in NCI-H929 treated with vehicle (DMSO) or 5nM bortezomib (indicated as bort) or
with 5nM bortezomib and 20mM Z-IETD-FMK for 24h. *Po0.01;
 Po0.05
miR-29b sensitizes MM cells to bortezomib-induced apoptosis
N Amodio et al
7
Cell Death and DiseaseshRNAs or pharmacologic inhibition by mithramycin-A
increase miR-29b levels. Therefore, our results demonstrate
thatamiR-29b-Sp1feedbackregulatoryloopindeedoccursin
MM cells, representing a target amenable of therapeutic
intervention.
It is well known that Sp1 levels are under proteasome
control, and proteasome inhibitors have been proven to
decrease Sp1 levels in leukemic cells.
44,50 We have found
thatinhibitionof cell proliferationandinduction ofapoptosisby
the proteasome inhibitor bortezomib, at concentrations that
are achievable in MM patients in vivo,
51 are associated with
Sp1 downregulation and miR-29b upregulation (Figure 6).
Importantly, peripheral blood primary CD138
þ cells collected
from a PCL patient 24h after bortezomib treatment showed
upregulation of miR-29b similar to that observed in MM cell
lines. This in vivo observation on PCL is currently under
extended analysis in a large cohort of patients. Noteworthy,
the clinical efﬁcacy of the proteasome inhibitor bortezomib
has been shown in the treatment of patients with refractory
and relapsed MM and other tumors.
52 An intriguing ﬁnding of
the present work was that bortezomib regulates the anti-MM
effects of miR-29b: in fact, bortezomib increased synthetic
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(h) Caspase 3/7 activity assay performed on SKMM1 cells transduced with the empty vector or antagomiR-29b and treated with 5nM bortezomib for 48h
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Cell Death and DiseasemiR-29b mimics-induced cytotoxicity on MM cells, whereas
miR-29b inhibition dampened bortezomib-induced apoptosis.
These results underscore the relevance of miR-29b, and
likely of its downstream targets, to apoptosis induction by
bortezomib,providingnovelinformationontheunsolvedissue
of unraveled bortezomib targets.
53 Our results could the
refore contribute to the understanding of the intracellular
functions of miR-29b and of the biochemical perturbations
underlying the apoptotic stimuli induced by miR-29b, imple-
menting previous observations on the in vitro anti-myeloma
activity of this miRNA.
32
Notably, our ﬁndings highlight a major role for PI3K/AKT
pathway in regulating miR-29b-Sp1 loop. In fact AKT over-
expression led to miR-29b downregulation and Sp1 upregula-
tion, whereas pharmacologic inhibition of PI3K by LY294002
had the opposite effect. Conversely, miR-29b behaves as a
negative regulator of PI3K/AKT pathway by reducing AKT
phosphorylation and its kinase activity on downstream AKT
substrate GSK-3b. At the same time, transfection of a
constitutively active AKT suppresses caspase 3/7 activity
induced by miR-29b. All together, these ﬁndings demonstrate
that PI3K/AKT is a negative regulator of miR-29b whose
proapototic activity involves functional downregulation of
AKT. These results highlight a novel exciting scenario and
provide new formal evidence for a major role of PI3K/AKT in
down-modulating miR-29b activity. Our ﬁndings of a pre-
minent role of the survival PI3K/AKT pathway in antagonizing
miR-29b activity complement its function of apoptosis
inducer also by MCL-1 downregulation, providing a wide
scenario of MM apoptosis derangement by miR-29b down-
regulation in MM.
In conclusions, our investigation demonstrates a relevant
in vitro and in vivo anti-MM apoptotic activity of miR-29b and
addsnovelinsightsintopathwaysregulatingmiRNAs-induced
apoptosis, providing the biological rationale for the use of
synthetic miR-29b mimics, alone or in combination with
bortezomib, as novel therapeutic strategy in MM.
Materials and Methods
Cell lines, primary cells, and drugs. Peripheral blood mononuclear cells
(PBMCs), BM mononuclear cells (BMMNCs), and primary MM cells from MM
patient BM aspirates, following informed consent and University Magna Graecia
IRB approval, were isolated using Ficoll-Hypaque density gradient sedimentation.
MM patient cells were separated from BM samples by antibody-mediated positive
selection using anti-CD138 magnetic activated cell separation microbeads
(Miltenyi Biotech, Gladbach, Germany).
MM cell lines were cultured in RPMI-1640 (Gibco, Life Technologies, Carlsbad,
CA, USA) supplemented with 10% fetal bovine serum (Lonza Group, Basel,
Switzerland). DOX-6 and LR-5 cell lines were kindly provided by Dr. Eduard
Thomson (University of Texas Medical Branch, Galveston, TX, USA); the IL-6-
dependent MM cell Line INA-6 (kindly provided from Dr. Renate Burger, University
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analyzed for miR-29b expression levels by quantitative RT–PCR. Normalization was performed using RNU44 snoRNA and DDCt calculations. Immunoblots show protein
levelsoftransfectedAKT(HAtag)andSp1intransfectedcells;GAPDHwasusedasloadingcontrol.*Po0.01.(b)QuantitativeRT–PCRofmiR-29binNCI-H929cellstreated
with 20mM LY294002 or vehicle (DMSO) for 48h. Immunoblot shows Sp1 and phosphorylated AKT at S473 protein levels in LY294002-treated cells. GAPDH was used as
loading control.
 Po0.05. (c) Caspase 3/7 activity assay was performed in NCI-H929 cells transfected with synthetic mir-29b or NC together with pcDNA.3.1-HA-myr-AKT
dominantactiveconstructorthesameamountoftheemptyvectorpcDNA3.1(indicatedasvector).Transfectedcellsweregrownin96-wellmicroplatesandluminescencewas
measuredafter48husingtheCaspase3/7Gloassay(Promega).*Po0.01.ResultsareexpressedasfoldincreaseofcaspaseactivitywithrespecttoNC-transfectedcells,of
atleastthreeindependent experiments.(d)Caspase3/7activityassaywasperformedinNCI-H929cellstransfectedwithsyntheticmir-29bor NCandthentreatedwith20mM
LY294002 or vehicle for 48h. (e) (Left panel) Immunoblot analysis of AKT, phosphorylated AKT at S473, phosphorylated GSK-3b at S9, GSK-3b, 4E-BP1 phosphorylated at
S65 and PTEN in NCI-H929 cells, 24h after transfection with synthetic mir-29b or NC; GAPDH was used as loading control. (Right panel) AKT activity was determined as
reported in Supplementary material and methods, 24h after transfection of NCI-H929 cells with synthetic miR-29b or NC; a-tubulin was used as loading control
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recombinant-human IL-6 as previously described.
54 BMSCs were established as
previously described.
55 Methylcellulose colony assays were performed in RPMI-
1640 medium containing 1.1% methyl-cellulose (STEMCELL Technologies Inc.,
Vancouver, Canada) and 20% FBS. Colony formation was scored at day 14 after
plating 1000 cells (SKMM1) or 500 cells (NCI-H929) in 24-well plates containing
1ml of methylcellulose medium. Mithramycin-A was purchased from Sigma-Aldrich
(St Louis, MO, USA) and dissolved in DMSO. Clinical grade bortezomib was purchased
from Millennium Pharmaceuticals (Takeda, Cambridge, MA, USA) and dissolved in sodium
chloride saline solution at 1mg/ml. Caspase 8 inhibitor Z-IETD-FMK and PI3K inhibitor
LY294002 were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA) and
Cell Signaling (Danvers, MA, USA), respectively.
miRNA expression proﬁling of CD138þ cells from MM patients.
Whole genome miRNAs proﬁling of puriﬁed (Z90%) PCS from BM aspirates of 40
untreated patients (38 MMs and 2 PCLs) was reported in our previous work.
56
Patients have been stratiﬁed according to the presence of the recurrent IGH
chromosomal translocations and cyclins D expression (TC classiﬁcation; see
Supplementary material and methods for details). The microarray consist of 60-
mer DNA probes synthesized in situ, which represent 723 human and 76 human
viral miRNAs from the Sanger database v 10.1. (Wellcome Trust Sanger Institute,
Hinxton, Cambridge, UK). miRNA data are available at GEO accession number
GSE17498.
Virus generation and infection of MM cells. The human Sp1
(NM_138473) mission shRNA set (Sigma) and the mission nontarget control
transduction virus (SHC002V; Sigma) were used to generate lentiviral particles in
HEK 293T packaging cells as previously described;
57 two rounds of transduction of
MM cells in the presence of 8mg/ml of polybrene (Sigma) were performed. Two days
after transduction, transduced cells were selected with 1mg/ml Puromycin (Sigma).
To generate Sp1-encoding retrovirus, HEK 293T cells were co-transfected with
10mg of pBABEpuro-Sp1 (kindly provided by Dr. Phyllis Dennery, University of
Pennsylvania), 10mg of pCMV-VSVG, and 4mg of PEQ-PAM and collected and
used to transduce MM cells. Transduced cells underwent three rounds of infection
(8h each round) and were selected in medium containing 1mg/ml puromycin.
To obtain cells stably expressing miR-29b, we used a feline immunodeﬁciency
lentivirus-based construct (System Biosciences, Mountain View, CA, USA),
consisting of the stem loop structure of miR-29b and 200bp of upstream and
downstream ﬂanking genomic sequence cloned into the pMIF-cGFPZeo-miR
plasmid. Packaging of the miR-29b constructs in pseudoviral particles was
performed in 293Ta cells using the Lenti-Pac FIV Expression Packaging Kit (FPK-
LvTR-20), according to the manufacturer’s instructions (Genecopoeia, Rockville,
MD, USA). After transfection of 293Ta cells, supernatants containing miR-29b
lentivirus were collected at 8-h intervals, ﬁltered, and used for two rounds of
transduction of SKMM1, U266 and RPMI-8226 cells (1 10
6) in the presence of
8mg/ml of polybrene (Sigma-Aldrich). Two days after transduction, selection with
200mg/ml Zeocin for 3 days was performed to achieve almost 100% transduced
cells. Empty lentivirus was used as a control for the experiments.
To obtain MM cells stably expressing antagomiR-29b, we used the lentiviral
vector miRZip-29b anti-miR-29b construct (System Biosciences); lentiviral particles
production and transduction were performed according to the above indicated
protocols. Selection was performed in medium containing 1mg/ml puromycin.
Quantitative real-time ampliﬁcation of miRNAs and mRNAs.
Total RNA from MM cells was prepared with the TRIzol Reagent (Invitrogen, Life
Technologies, Carlsbad, CA, USA) according to the manufacturer’s instructions.
The single-tube TaqMan miRNA assays (Assay Id 000413, Applied Biosystems,
Life Technologies) was used to detect and quantify mature miR-29b according
to the manufacturer’s instructions, by the use of iQ5 multicolor detection system
(Bio-Rad, Berkeley, CA, USA). miR-29b expression was normalized on RNU44
(Applied Biosystems, Assay Id 001094).
For mRNA dosage studies, oligo-dT-primed cDNA was obtained using the High
Capacity cDNA Reverse Transcription Kit (Applied Biosystems) and then used as
template to quantify CDK6 (Hs01026371_m1), MCL-1 (Hs01050896_m1)
and Sp1 (Hs00412720_m1) levels by TaqMan assay (Applied Biosystems);
normalization was performed with GAPDH (Hs03929097_g1). Comparative real-
timepolymerasechain reaction(RT–PCR)was performedin triplicate,including no-
template controls. Relative expression was calculated using the comparative cross
threshold (Ct) method.
58
Luciferase reporter experiments. The pGL3 Luciferase plasmid contain-
ing the miR-29a/b1 promoter (nts –1530 þ165) was a kind gift of Dr. J Mott
(University of Nebraska Medical Center). Transfections were performed by
electroporation and renilla luciferase from pCMV-RL was included to normalize
expression of ﬁreﬂy luciferase. The 30UTR segments containing the target sites for
miR-29b from the Sp1 gene corresponding to the sites of interaction with miR-29b,
were cloned in pEZX-MT01 vector and purchased from Genecopoeia (product Id
HmiT017640b-MT01). MM cells were electroporated as above described using
5mg of the ﬁreﬂy luciferase reporter; for each plate, 100nM of the synthetic miR-
29b or miR-NC were used. Fireﬂy and Renilla luciferase activities were measured
consecutively using the dual-luciferase assay kit (Promega Corporation, Madison,
WI, USA) 24 and 48h after transfection. Data are expressed as luminescence from
ﬁreﬂy luciferase divided by luminescence from renilla luciferase.
Animals and in vivo model of human MM. Male CB-17 severe
combined immunodeﬁcient (SCID) mice (6- to 8-weeks old; Harlan Laboratories,
Inc., Indianapolis, IN, USA) were housed and monitored in our Animal Research
Facility. All experimental procedures and protocols had been approved by the
Institutional Ethical Committee (Magna Graecia University) and conducted
according to the protocols approved by the National Directorate of Veterinary
Services (Italy). In accordance with the institutional guidelines, mice were killed
when their tumors reached 2cm in diameter or in the event of paralysis or major
compromise in their quality of life, to prevent unnecessary suffering. For our study,
3 10
6 NCI-H929 cells stably expressing miR-29b by lentivirus-based construct,
the pMIF-miR-29b plasmid, or transduced with empty vector (pMIF) as control,
were injected sc into the ﬂank of 10 SCID mice. Tumor sizes were measured
weekly in two dimensions using a caliper, and volume was calculated using the
formula: V¼0.5 a b
2, where a and b are the long and short diameter of the
tumor, respectively, until the tumor was palpable.
54 In this model, tumors were
palpable approximately 2 weeks after injection.
In vivo detection of the tumor mass in xenografted mice was performed using
IVISLUMINAIIImagingSystem(CaliperLifesciences,Hopkinton,MA,USA).Then,
tumor sizes were measured every 2 days until the day of ﬁrst mouse kill. Tumors
were retrieved from animals and placed in 10% formalin for histology or in RNAlater
(Ambion, Carlsbad, CA, USA) for RNA isolation.
Histology and immunohistochemistry. Retrieved tumors from animals
were immediately ﬁxed in 4% buffered formaldehyde for 24h at 41C, washed,
dehydrated, and embedded in parafﬁn. For the light microscopy analysis, sections
were cut (4mm), mounted on poly-lysine slides, and stained with H&E. For
immunohistochemistry stainings, 2-mm thick sections were in a Bond Max
Automated Immunohistochemistry according to the following protocol. First,
tissues were deparafﬁnized and pretreated with the Epitope Retrieval Solution 2
(EDTA-buffer pH8.8) at 981C for 20min After washing steps, peroxidase blocking
was carried out for 10min using the Bond Polymer Reﬁne. Tissues were again
washed and then incubated with the primary antibody directed against Ki-67
(Dako, Milano, Italy, clone: MIB-1; 1:150) or capase-3 (Novocastra, Newcastle
upon Tyne, UK, clone: JHM62; 1:500). Subsequently, tissues were incubated with
polymer for 10min and developed with DAB-Chromogen for 10min Slides were
counterstained with hematoxylin.
Statistical analysis. Student’s t-test, two-tailed and log-rank test were
used to evaluate statistical signiﬁcance by GraphPad software (GraphPad
Software, Inc., La Jolla, CA, USA, www.graphpad.com). Graphs were obtained
using SigmaPlot version 11.0 (Systat Software, Inc., San Jose, CA, USA).
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